Opinion

Video

Implementing PET RANO 1.0 Response Criteria in Glioblastoma Assessment

Author(s):

Nathalie Albert, MD ,Matthias Preusser, MD

Medical experts engage in a discussion on the PET RANO 1.0 Response Criteria, which provides guidelines for evaluating treatment response in patients with brain tumors, taking into account both measurable PET-positive disease and non-PET-positive disease, as assessed through initial baseline imaging and subsequent follow-up scans.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!
Related Videos
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
Related Content
FDA grants priority review to zongertinib in HER2-mutant NSCLC and dordaviprone for recurrent H3K27M+ diffuse glioma, and more from OncLive this week.
February 22nd 2025

The OncFive: Top Oncology Articles for the Week of 2/16

Drs Camidge and Boire discuss Dr Boire's journey to becoming a physician-scientist, moments in her career that shaped her fascination with neurology, and how studying human biology at the cellular level can ultimately help improve the lives of patients with cancer.
January 22nd 2025

A Nuanced Understanding of Cellular Biology Advances Neuro-Oncology Practice: With D. Ross Camidge, MD, PhD; and Adrienne A. Boire, MD, PhD

Here is your snapshot of all therapeutic options that were approved by the FDA in January 2025 spanning tumor types.
February 3rd 2025

OncLive’s FDA Approval Report: The Regulatory Rundown for January 2025

Federico Outlines Needs, Nuances, and Necessities in Neuroblastoma Treatment
May 10th 2021

Federico Outlines Needs, Nuances, and Necessities in Neuroblastoma Treatment

Neuroblastoma | Sebastian Kaulitzki – stock.adobe.com
January 7th 2025

EU Approval Is Sought for Eflornithine in High-Risk Neuroblastoma

Image Credit: © Cornflakesei - stock.adobe.com
January 2nd 2025

FDA Approval Sought for Dordaviprone in Recurrent H3K27M+ Diffuse Glioma